Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-18

FDA Approved: NEPHROSCAN — Original Application (Theragnostics Inc)

View source ↗

Summary

FDA approved NEPHROSCAN (SUCCIMER) from Theragnostics Inc. through an original NDA. It is intended as a renal imaging agent to assess kidney function.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NEPHROSCAN (SUCCIMER)

Snippet

ORIG AP for NEPHROSCAN (SUCCIMER)